Your trusted source for investing success

Tag: genetic mutation

Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)

Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced results of a six-month open label Phase 2a study that also included an additional six-month follow-up period investigating trehalose in patients with Spinocerebellar Ataxia Type 3 (SCA3).The objectives of the study were to establish safety and tolerability of

How Personalized Medicine Can Change Your Investment Strategy

How Personalized Medicine Can Change Your Investment Strategy

Pharmaceutical companies have developed numerous strategies to counter the patent cliff. One such tactic? Capitalizing on the personalized medicine market. As it turns out, this niche market is less vulnerable to the patent cliff—which may make it attractive to pharmaceutical companies and investors alike.

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network